



Implanet announces its annual report on the liquidity contract with TSAF – Tradition Securities

Bordeaux, Boston, January 15, 2019

Pursuant to the liquidity contract entrusted to TSAF – Tradition Securities by IMPLANET (Euronext: ALIMP, FRO010458729, PEA-PME eligible), on 31 December 2018, the following assets appeared on the liquidity account:

- Number of shares: 170,500
- Cash balance of the liquidity account: €31,780.10

As a reminder, at the time of the last half-yearly report on 30 June 2018, the following resources were booked to the liquidity account:

- Number of shares: 160,000
- Cash balance of the liquidity account: €34,349.25

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 46 staff and recorded 2017 sales of €7.8 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the BEOCABSA, OCA, BSA and the number of shares outstanding, is available on its website: <http://www.implanet-invest.com/suivi-des-actions-80>

IMPLANET
Ludovic Lastennet
CEO
Tel. : +33 (0)5 57 99 55 55
investors@implanet.com

NewCap
Investor Relations
Julie Coulot
Tel. : +33 (0)1 44 71 20 40
implanet@newcap.eu

NewCap
Media Relations
Nicolas Merigeau
Tel. : +33 (0)1 44 71 94 98
implanet@newcap.eu